The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Icotinib versus vinorelbine/platinum as adjuvant therapy in stage II-IIIA non-small cell lung cancer with EGFR-mutations: A multicenter, randomized, positive-controlled, phase 3, indication-expanding study (EVIDENCE, CCTC-1501).
 
Jianxing He
No Relationships to Disclose
 
Wenhua Liang
No Relationships to Disclose
 
Shidong Xu
No Relationships to Disclose
 
Shaofa Xu
No Relationships to Disclose
 
Jianying Zhou
No Relationships to Disclose
 
Weimin Mao
No Relationships to Disclose
 
Qun Wang
No Relationships to Disclose
 
Xiuyi Zhi
No Relationships to Disclose
 
Fenlai Tan
Employment - Betta Pharmaceuticals
 
Lieming Ding
Employment - Betta Pharmaceuticals
 
Caicun Zhou
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Lilly; Roche
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Lilly; Roche